Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030849 · ClinicalTrials.gov registry record · Phase 2
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
A Phase 2 study of Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
NCT00030849 is a Phase 2 study of Lymphoma that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 5 study locations across 4 states.
The verdict
NCT00030849, a Phase 2 study of Lymphoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bexarotene with interferon alfa in treating patients who have cutaneous T-cell lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interferon alfa
- DRUG bexarotene
Study Locations (5)
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania Medical Center - Philadelphia
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030849
The ClinicalTrials.gov registry entry for NCT00030849 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which recombinant interferon alfa is the first listed.
NCT00030849 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00030849 about?
NCT00030849 is a clinical study titled "Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effect...
What is the current status of trial NCT00030849?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-10. Estimated completion is 2009-12.
What conditions does trial NCT00030849 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00030849?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), bexarotene (DRUG).
Who is sponsoring clinical trial NCT00030849?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00030849 being conducted?
This trial has 5 study locations across Florida, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.